biostudies-literatureUnknown10Castaneda-Puglianini OImmunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody-drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success. Bispecific antibodies represent a novel immunotherapeutic approach for the treatment of several malignancies, in particular non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Early-phase studies have shown encouraging clinical activity in poor-risk B cell NHL and MM. Several constructs are currently available and in clinical development for the treatment of these malignancies. Here, we present a narrative review of the most current data on bispecific antibodies in B cell NHL and MM.Drugs in contexthttps://www.ebi.ac.uk/biostudies/studies/S-EPMC8462994biostudies-literatureBispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma.PMC8462994Chavez JCCastaneda-Puglianini OfalseBispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma.Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody-drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success. Bispecific antibodies represent a novel immunotherapeutic approach for the treatment of several malignancies, in particular non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Early-phase studies have shown encouraging clinical activity in poor-risk B cell NHL and MM. Several constructs are currently available and in clinical development for the treatment of these malignancies. Here, we present a narrative review of the most current data on bispecific antibodies in B cell NHL and MM.2021-01-01T00:00:00Z20212022-02-11T12:24:41.176Z2022-02-11T12:24:41.176ZS-EPMC84629943460345910.7573/dic.2021-2-4